This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Case of Cholesterol-Lowering Interventions in the Secondary Prevention of Coronary Heart Disease

Roberto Marchioli, MD; Rosa Maria Marfisi; Fabrizio Carinci, MS; Gianni Tognoni, MD

Arch Intern Med. 1996;156(11):1158-1172.

Abstract
Objective
To evaluate, in the comprehensive scenario of "evidence-based" medicine, the transferability of the results of published randomized clinical trials and meta-analyses on cholesterol-lowering interventions to clinical practice.

Method
Overview of randomized clinical trials on cholesterol-lowering interventions in the secondary prevention of coronary heart disease.

Results
The present overview on secondary prevention of coronary heart disease included 34 trials with cholesterol-lowering interventions in 24 968 individuals. There was a 12.5% mortality in the group that was allocated active intervention and a 17.2% mortality in the control group (risk reduction, 13%; 95% confidence interval, —19% to —6%). Coronary and cardiovascular odds of deaths were significantly reduced. No clear association was found between noncoronary mortality and cholesterol-lowering interventions. Baseline total cholesterol levels had no clear influence on total mortality. Intermediate (10%-20%) and high (>20%) total cholesterol reductions were associated with similar reductions in the odds of death (—23% and —30%, respectively). No conclusion could be reached for patients who were less represented in the studies (ie, women and elderly persons). Patients with more complicated baseline clinical conditions (eg, congestive heart failure) had little nonsignificant benefit from cholesterol-lowering interventions.

Conclusions
The effect of cholesterol-lowering interventions at least in the secondary prevention of coronary heart disease can be considered as established, but the transferability of such results to real-life patients remains the critical, unanswered question.

(Arch Intern Med. 1996;156:1158-1172)

Author Affiliations
From the Department of Clinical Pharmacology and Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri—Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Nogueira and Weir
CJASN 2007;2:766-785.
ABSTRACT | FULL TEXT  

Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure
Tavazzi et al.
Eur J Heart Fail 2004;6:635-641.
ABSTRACT | FULL TEXT  

Hemostatic Effects of Atorvastatin Versus Simvastatin
Kadikoylu et al.
The Annals of Pharmacotherapy 2003;37:478-484.
ABSTRACT | FULL TEXT  

Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations; GISSI-Prevenzione mortality risk chart
Marchioli et al.
Eur Heart J 2001;22:2085-2103.
ABSTRACT  

Clinical Outcomes in Statin Treatment Trials: A Meta-analysis
Ross et al.
Arch Intern Med 1999;159:1793-1802.
ABSTRACT | FULL TEXT  

Getting research findings into practice: When to act on the evidence
Sheldon et al.
BMJ 1998;317:139-142.
FULL TEXT  

Mouse models of human disease. Part II: recent progress and future directions.
Bedell et al.
Genes Dev. 1997;11:11-43.